485 patents
Page 15 of 25
Utility
Formulation of Human Antibodies for Treating Tnf-alpha Associated Disorders
22 Apr 21
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
Hans-Juergen Krause, Lisa Baust, Michael Dickes
Filed: 18 Dec 20
Utility
Modulators of Ror-gamma
1 Apr 21
David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Linghang Zhuang
Filed: 17 Sep 20
Utility
Crystalline forms of a Bruton's tyrosine kinase inhibitor
30 Mar 21
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 18 Nov 20
Utility
Enzymatic Processes for the Preparation of (±)-2-(DIFLUOROMETHYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC Acid and (±)-2-(VINYL)-1-(ALKOXYCARBONYL)-CYCLOPROPANECARBOXYLIC Acid
25 Mar 21
Disclosed are methods of synthesizing racemic 2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and 2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acids and their salts, such as the dicyclohexylamine salt.
Michael J. Abrahamson, Sanjay R. Chemburkar, Angelica B. Kielbus, Russell D. Cink
Filed: 11 May 20
Utility
Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
23 Mar 21
Described herein are mutations that confer resistance to treatment with a BTK inhibitor.
Betty Chang, Joseph J. Buggy, Susanne M. Steggerda
Filed: 23 Jul 13
Utility
Protein tyrosine phosphatase inhibitors and methods of use thereof
23 Mar 21
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
Filed: 18 Sep 20
Utility
Inhibitors of Brutons Tyrosine Kinase
11 Mar 21
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk).
Gordana B. Atallah, Wei Chen, Zhaozhong J. Jia, Alfonso Pozzan, Luca F. Raveglia, Riccardo Zanaletti
Filed: 17 Jul 19
Utility
Tetracyclic Bromodomain Inhibitors
11 Mar 21
Steven D. Fidanze, Dachun Liu, Robert A. Mantei, Keith F. McDaniel, John Pratt, George S. Sheppard, Le Wang, Andrew Bogdan, James H. Holms, Justin D. Dietrich, Jasmina Marjanovic, Lisa A. Hasvold, Yujia Dai
Filed: 16 Nov 20
Utility
Crystalline Forms of a Brutons Tyrosine Kinase Inhibitor
11 Mar 21
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof.
Norbert Purro, Mark S. Smyth, Erick Goldman, David D. Wirth
Filed: 18 Nov 20
Utility
Prolactin Receptor Binding Proteins and Uses Thereof
11 Mar 21
The present invention encompasses PRLR binding proteins.
Mark Anderson, Jieyi Wang, Archana Thakur, Debra Chao, Chung-Ming Hsieh, Qian Zhang, Edward B. Reilly, Enrico L. Digiammarino, Kenton L. Longenecker, Russell A. Judge, David A. Egan, Charles W. Hutchins
Filed: 24 Mar 20
Utility
Novel Tricyclic Compounds
4 Mar 21
Neil WISHART, Maria A. ARGIRIADI, David J. CALDERWOOD, Anna M. ERICSSON, Bryan A. FIAMENGO, Kristine E. FRANK, Michael M. FRIEDMAN, Dawn M. GEORGE, Eric R. GOEDKEN, Nathan S. JOSEPHSOHN, Biqin C. LI, Michael J. MORYTKO, Kent D. STEWART, Jeffrey W. VOSS, Grier A. WALLACE, Lu WANG, Kevin R. WOLLER
Filed: 13 Jun 19
Utility
Anti-prlr Antibody-drug Conjugates (Adc) and Uses Thereof
4 Mar 21
Provided are antibody drug conjugates that bind PRLR, in particular human PRLR, their methods of making, and uses thereof.
Edward B. Reilly, Mark Anderson
Filed: 6 Apr 20
Utility
Levodopa and Carbidopa Intestinal Gel and Methods of Use
4 Mar 21
The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
Alexandru DEAC, Ye HUANG, John M. LIPARI, Alexander RUGGLES, Thin Yu TUN
Filed: 21 Apr 20
Utility
Controlled Release Pharmaceutical Compositions for Acid-labile Drugs
4 Mar 21
An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein.
George Shlieout, Claus-Juergen Koelln, Frithjof Sczesny, Jens Onken, Andreas Koerner
Filed: 12 Nov 20
Utility
Anti-BMPR1B antibodies and methods of use
2 Mar 21
Provided are novel anti-BMPR1B antibodies and antibody drug conjugates, and methods of using such anti-BMPR1B antibodies and antibody drug conjugates to treat cancer.
Somdutta Roy, Laura Saunders, Casey Franklin, Kevin Martinez, Sarah Fong, Zhao Huang, Silvia Juarez, Alina He, Kathryn A. Loving, Sandro Vivona
Filed: 21 Apr 17
Utility
Inhibitors of the Menin-mll Interaction
25 Feb 21
The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.
Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
Filed: 1 Apr 20
Utility
Levodopa and Carbidopa Intestinal Gel and Methods of Use
18 Feb 21
The present disclosure relates to (a) an improved pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent (b) methods of producing the pharmaceutical composition and (c) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
Rajkumar CONJEEVARAM, Alexandru DEAC, Ye HUANG, Sean E. MACKEY, Randy A. MENGES, Jayne ZIMMERMAN
Filed: 18 Mar 20
Utility
Bromodomain Inhibitors
18 Feb 21
Marlon Cowart, Steven Fidanze, Lisa Hasvold, Dachun Liu, Keith McDaniel, John Pratt, George Sheppard, Le Wang
Filed: 26 May 20
Utility
Methods and compositions for treating asthma using anti-IL-13 antibodies
16 Feb 21
The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.
Catherine Tripp
Filed: 27 Jun 17
Utility
Systems and Methods for Identifying Protein Aggregates In Biotherapeutics
11 Feb 21
Systems and methods for inspecting particles in a liquid beneficial agent are provided.
Edmund Matayoshi, Sheng Tu, Jie Wang
Filed: 28 Jul 20